Vireo Growth (VREOF) Cash & Current Investments (2020 - 2026)
Vireo Growth (VREOF) posted Cash & Current Investments of $153.2 million for Q1 2026, up 7.28% sequentially from $142.8 million in Q4 2025, and up 74.19% YoY from $88.0 million in Q1 2025.
Vireo Growth (VREOF) Cash & Current Investments (2020 - 2026) Analysis & Trends
Vireo Growth has reported Cash & Current Investments for 7 years, with the latest figure at $153.2 million in Q1 2026.
- Quarterly Cash & Current Investments rose 74.19% year-over-year to $153.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $153.2 million (up 74.19% YoY) and the FY2025 annual result came in at $142.8 million, up 52.12% from the prior year.
- Cash & Current Investments advanced to $153.2 million in Q1 2026 per VREOF's latest filing, from $142.8 million in the prior quarter.
- Over five years, Cash & Current Investments peaked at $153.2 million in Q1 2026 and troughed at $7.3 million in Q3 2024.
- A 5-year average of $49.6 million and a median of $17.0 million in 2022 frame the typical range for Cash & Current Investments.
- The sharpest annual moves came in 2022 and 2025: Cash & Current Investments sank 78.79% in 2022, then soared 1528.49% in 2025.
- Over 5 years, Cash & Current Investments stood at $15.1 million in 2022, then advanced by 18.17% to $17.9 million in 2023, then soared by 424.36% to $93.9 million in 2024, then jumped by 52.12% to $142.8 million in 2025, then gained by 7.28% to $153.2 million in 2026.
- According to Business Quant data, Cash & Current Investments over the past three periods registered $153.2 million, $142.8 million, and $118.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.05 Bn | 43.08 Bn | - | 963.33 Mn |
| 2 | Teva Pharmaceutical Industries | 43.39 Bn | 39.74 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 1.68 Bn |
| 4 | Takeda Pharmaceutical | 28.78 Bn | 22.99 Bn | 5.10 Bn | 5.80 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 2.66 Bn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 389.80 Mn |
| 8 | Elanco Animal Health | 11.92 Bn | 11.39 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 9.99 Bn | - | 164.00 Mn |
| 10 | Vireo Growth | 491.44 Mn | 349.14 Mn | 95.30 Mn | 142.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 153.20 Mn |
| Dec 31, 2025 | 142.80 Mn |
| Sep 30, 2025 | 118.55 Mn |
| Jun 30, 2025 | 100.41 Mn |
| Mar 31, 2025 | 87.95 Mn |
| Dec 31, 2024 | 93.87 Mn |
| Sep 30, 2024 | 7.28 Mn |
| Jun 30, 2024 | 11.23 Mn |
| Mar 31, 2024 | 12.60 Mn |
| Dec 31, 2023 | 17.90 Mn |
| Sep 30, 2023 | 13.30 Mn |
| Jun 30, 2023 | 11.35 Mn |
| Mar 31, 2023 | 10.35 Mn |
| Dec 31, 2022 | 15.15 Mn |
| Sep 30, 2022 | 21.84 Mn |
| Jun 30, 2022 | 16.97 Mn |
| Mar 31, 2022 | 8.60 Mn |
| Dec 31, 2021 | 15.16 Mn |
| Sep 30, 2021 | 11.78 Mn |
| Jun 30, 2021 | 20.83 Mn |